GlassScriptPhysician profile
Caitlin Brooks Piteck
NPI 1528749124
$4,834.76
in general payments reported to CMS, 2019-2025
41 companies · $1,905 in 2025
The $1,905 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $685 · 2024: $2,245 · 2025: $1,905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,815 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,815.14 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $437.92 | 2023-2025 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals LP | $420.61 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $394.78 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $392.55 | 2023-2025 | Repatha, Otezla, Prolia |
| Novartis Pharmaceuticals Corporation | $292.09 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $274.20 | 2023-2025 | Xifaxan, Trulance, Relistor |
| Hologic Sales and Service, LLC | $267.88 | 2023-2025 | Aptima |
| Gilead Sciences, INC. | $249.30 | 2024-2025 | Descovy |
| Glaxosmithkline, LLC. | $227.71 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $210.25 | 2023-2025 | Mounjaro, Jardiance, Kisunla |
| Abbvie INC. | $181.43 | 2023-2025 | |
| Genzyme Corporation | $154.24 | 2024-2025 | |
| Viiv Healthcare Company | $137.92 | 2025 | Apretude |
| Inspire Medical Systems, INC. | $121.92 | 2023-2025 | Inspire |
| Boston Scientific Corporation | $94.05 | 2024 | Watchman Flx |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $88.09 | 2024-2025 | Nexletol |
| Organon LLC | $77.32 | 2024-2025 | Nexplanon |
| Phadia US INC. | $57.96 | 2024-2025 | Immunocap |
| Pfizer INC. | $56.27 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $52.18 | 2025 | Spravato |
| Sanofi-Aventis U.S. LLC | $51.40 | 2024-2025 | |
| Antares Pharma, INC. | $51.27 | 2025 | Xyosted |
| Philips North America LLC | $46.45 | 2024-2025 | (Ck7) Extended Holter, Extended Holter |
| Dexcom, INC. | $46.22 | 2023-2024 | Dexcom G6 Transmitter |
| Alk-Abello, INC | $45.64 | 2024 | Grastek, Odactra, Ragwitek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.63 | 2024-2025 | |
| Qiagen, LLC | $39.84 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.42 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $28.37 | 2024 | Rexulti |
| Incyte Corporation | $27.12 | 2025 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $26.09 | 2025 | Austedo Xr |
| Tms Neurohealth Centers INC. | $25.40 | 2025 | Tms Neurohealth Centers INC. |
| Grifols USA, LLC | $24.58 | 2024 | Prolastin-C Liquid |
| Astellas Pharma US INC | $24.33 | 2024 | Veozah |
| Irhythm Technologies, INC. | $23.84 | 2024 | Zio Xt Patch, Zio Monitor |
| Neurelis, INC. | $22.70 | 2024 | Valtoco |
| Coopersurgical, INC. | $21.57 | 2024 | Paragard T 380a |
| Corcept Therapeutics | $19.88 | 2025 | Korlym |
| Optinose US, INC. | $19.42 | 2024 | |
| Cequr Corporation | $14.05 | 2023 | Cequr Simplicity |
| Avion Pharmaceuticals | $13.87 | 2023 | Methylphenidate Hydrochloride |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Piteck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.